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doi:10.1016/j.ejvs.2008.11.013Abstract Background: Although endovenous laser ablation for varicose veins is replacing
surgical stripping, proper economic evaluation with adequate follow-up in a randomised clin-
ical trial is important for considered policy decisions regarding the implementation of new
techniques.
Methods: Data from a randomised controlled trial comparing cryostripping and endovenous
laser ablation in 120 patients were combined to study Short Form (SF) 6D outcome, costs
and cost-effectiveness 2 years after treatment. Incremental cost per quality-adjusted life year
(QALY) gained 2 years after treatment was calculated using different strategies, and uncer-
tainty was assessed with bootstrapping.
Results: Over the total study period, mean SF-6D scores improved slightly from 0.78 at baseline
to 0.80 at 2 years for patients who underwent cryostripping and from 0.77 to 0.79 for patients
who underwent endovenous laser. QALY (SF-6D) was 1.59 in patients who underwent cryostrip-
ping and 1.60 in patients who underwent endovenous laser 2 years after treatment. The costs
of cryostripping and endovenous laser per patient were V2651 and V2783, respectively. Boot-
strapping indicated that cryostripping was associated with an incremental cost-effectiveness
ratio of V32 per QALY gained. With regard to different strategies, outpatient cryostripping
was less costly and more effective 2 years after treatment.selhoff, Department of Surgery, Mesos Medical Centre, Van Heuven Goedhartlaan 1, 3527 Utrecht, CE,
.
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358 B.C.V.M. Disselhoff et al.Conclusion: In this study, in terms of costs per QALY gained, outpatient cryostripping appeared
to be the dominant strategy, but endovenous laser yielded comparable outcomes for a rela-
tively little additional cost.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.The most common treatment for patients with varicose
veins due to reflux in the great saphenous vein (GSV) is
ligation of the vein and its tributaries at the saphenofe-
moral junction (SFJ), followed by stripping of the GSV from
the groin to just below the knee. Since its introduction, the
authors have used cryostripping for varicose veins because
it is less traumatic, has lower rates of postoperative
morbidity and has complication rates similar to those of
traditional surgery.1e3 Recently, endovenous laser ablation
(EVLA) was introduced as an alternative to the surgical
treatment of varicose veins. The apparent simplicity of this
procedure and high patient satisfaction have resulted in
fast dissemination of the technique, despite lack of
evidence regarding the balance between costs and effects.
Several authors4e6 have claimed that EVLA is as effective as
surgical stripping, but with lower rates of postoperative
morbidity and activity impairment and with recurrence
rates no worse than those of surgical stripping. However,
these benefits need to be balanced against the more
expensive equipment required for EVLA. Proper economic
evaluation with adequate follow-up in a randomised clinical
trial provides information to support considered decision
making regarding the implementation of new techniques.
Ultimately, the goal is to provide evidence for a new
guideline on the standard of treatment for varicose veins.
This article describes a comparison of costs and cost-
effectiveness based on the randomised controlled trial
comparing the 2-year results of cryostripping and EVLA in
patients with primary varicose veins due to GSV reflux.Patients and Methods
An economic analysis was carried out alongside a rando-
mised clinical trial (RCT) comparing cryostripping and EVLA
treatments for varicose veins. The design and methods of
this RCT have been described elsewhere.5 In brief, patients
(aged between 19 and 75 years) with primary symptomatic
varicose veins (CEAP clinical class C2 venous disease7), who
gave informed consent, and had GSV reflux from the groin
to below the knee, were randomly assigned, using
numbered and sealed envelopes, to two treatment groups.
According to patient preference, the procedures were
performed as day-case procedures under regional or
general anaesthesia or as outpatient procedures with
tumescent local anaesthesia. Saphenous trunks were
stripped or ablated according to the assigned procedure,
but tributaries and varices were not removed during the
initial procedure. Six weeks later, residual side branches
and accessory saphenous veins were treated with scle-
rotherapy or Mu¨ller phlebectomy with the intention to
remove all varicosities. At the 6-, 12- and 24-month follow-
up, the requirement for additional procedures such as
saphenofemoral ligation, saphenopopliteal ligation (SPL),
sclerotherapy and Mu¨ller phlebectomy was recorded.The principal outcome measure for this study was clin-
ical effectiveness at 2 years, as measured using the Short
Form (SF) 6D. The SF-6D is a single preference-based
measure of health representing overall quality of life
derived from the SF368 health-status questionnaire using
the method described by Brazier et al.9 Utility scores for
the SF-6D were recorded at baseline and at 6, 12 and 24
months of follow-up. The SF-6D results in a numeric score
representing the health status. A value of 1 represents the
best health state, and 0 represents death. Using linear
interpolation for the periods between measurements, we
calculated the quality-adjusted life years (QALYs) until 2
years after treatment by determining the individual area
under the curve.
In the Netherlands, unilateral day-case surgical stripping
procedure of the GSV, with a disposable vein stripper, costs
V1888, and unilateral outpatient treatments cost V1571.
These costs are based on guideline prices according to the
Dutch College Rates of Health (http://www.ctg-zaio.nl)
and are estimated treatment costs per patient. The costs of
cryostripping and endovenous laser are similar, except for
additional equipment. The additional equipment costs
were based on the actual costs of purchase in 2003.
Although this may not result in an exact estimate of the real
costs, we used the same methods in both interventions in
this study. In order to perform cryostripping, a cryoappar-
atus (Erbe Benelux, Werkendam, The Netherlands) had
been purchased for V6667. Equipment depreciation and
interest costs were calculated, in accordance with the
Dutch Costing Manual issued by the National Health Insur-
ance Council,10 resulting in an additional cost of V6 per
cryostripping procedure. Additional costs for the probes
and nitrogen tank were approximately V48 per patient,
resulting in a total cost of V1625 and V1942 per patient for
outpatient and day-case treatments, respectively. In the
case of EVLA, a laser (Diomed D 15, Diomed Inc., Andover,
MA, USA) and a duplex ultrasound system (Sonosite 180
plus, Sonosite, Bothell, WA, USA) had been purchased for
V31 568 and V23 940, respectively, resulting in additional
equipment cost per EVLA of approximately V26 and V20
per patient, respectively. In addition, a sterile-procedure
laser kit worth V314 per patient resulted in the total cost of
V1931 V2248 per patient for outpatient and day-case
treatments, respectively. Therefore, additional cost per
EVLA was V306 compared to cost of cryostripping. During
the study period, additional outpatient treatment costs
were saphenofemoral or saphenopopliteal ligation (V1571
per patient), sclerotherapy (V453 per patient) and Mu¨ller
phlebectomy (V996 per patient). These costs were also
based on guideline prices according to the Dutch College
Rates of Health. The number of days of sick leave was
recorded and the cost of productivity loss was based on the
friction-cost method,11 by which production loss over time
is estimated by assuming that loss in production will be
restricted to a period needed for the employer to adapt to
Table 1 Baseline characteristics
Characteristics Cryostripping
(nZ 60)
Endovenous laser
(nZ 60)
Sex ratio (F:M) 42:18 41:19
Age (range (years))a 49 (19e73) 46 (22e74)
Occupation
Unemployed 10 13
Light physical work 19 22
Medium physical work 18 18
Heavy physical work 3 1
Retired 10 6
In GSV, 2 cm below SFJa
Diameter (cm) 0.93 (0.6e2.1) 1.01 (0.6e1.9)
Reflux time (s) 3.88 (0.5e6) 3.72 (0.7e6)
a Values are presented as means (range). Values in paren-
theses are percentages unless indicated otherwise. GSV, great
saphenous vein; SFJ, saphenofemoral junction.
Table 2 Costs (V) of cryostripping and endovenous laser
until 2 years after treatment
Cryostripping
(nZ 60)
Endovenous laser
(nZ 60)
Costs of initial treatment
Initial treatment 109 793 106 306
Additional equipmenta 3460 21 600
Costs of additional
treatment at 6 weeks
Mu¨ller phlebectomy 1992 996
Sclerotherapy 14 949 16 308
Costs of additional
treatment at 2 years
Adjunctive SFJ ligation 0 4713
Sclerotherapy 7701 3624
Phlebectomy 0 0
Small saphenous
vein ligation
3142 3142
Costs from
sick leave
17 812 10 262
Total costs
of treatment
158 849 166 951
a Cost included depreciation, interest and annual
maintenance.
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friction period was 123 days in 2003e2004, implying that
absence from work beyond 123 days would not lead to
a further loss of productivity. Productivity loss was fixed at
a mean of 80% of V41 per hour.
For economic evaluation, the estimates of QALY (SF-6D)
gained at the 2-year follow-up were chosen as the primary
measure of effect. The balance between costs and effects
of cryostripping and EVLA was expressed in terms of
incremental costs per QALY gained. The incremental cost-
effectiveness ratio was calculated by dividing the differ-
ence in costs during the 2-year period by the difference in
QALYs. A negative incremental cost-effectiveness ratio may
imply a negative cost difference (cost savings) and positive
health effects, or a positive cost difference (extra costs)
and negative health effects. Likewise, positive incremental
cost-effectiveness ratios may be obtained by positive cost
differences and positive health effects or negative cost
differences and negative health effects. To assess the
robustness of the results of the RCT, we repeated the
comparisons for different strategies: day-case treatment,
outpatient treatment and outpatient treatment in combi-
nation with a 50% reduced price for the EVLA kit. We
started the study in 2003 with a V341 price for the EVLA kit.
In 2008, since the procedure has become more common,
the price has been reduced to V172.
Statistical Analysis
All economic analyses were carried out on an intention-to-
treat basis. Data on outcomes were collected prior to and
at 6, 12 and 24 months after treatment. Incomplete ques-
tionnaires were returned for completion. Costs and health
outcomes were analysed using SAS version 9.1.3 (SAS Inc.,
Cary, NC, USA) and Microsoft Excel databases (Microsoft,
Redmond, WA, USA). Data are presented as means with 95%
confidence intervals (CIs) unless indicated otherwise. Cost-
effectiveness planes were used to depict the joint distri-
bution of incremental costs and effects, where incremental
costs and effects are on the Y- and X-axis, respectively.
Uncertainty regarding the results was assessed using boot-
strapping (nZ 500), in which the original data were used to
provide an empirical estimate of the sampling distribution
through repeated re-sampling from the observed data.12
Student’s t-test was used for comparison of results with
normal distribution. The ManneWhitney U-test was used for
comparison of skewed data. The significance level was set
at p< 0.05.
Results
The clinical results of the randomised controlled trial have
been reported elsewhere.2 Briefly, between June 2003 and
July 2005, 120 patients were equally randomised to cry-
ostripping or EVLA. Baseline characteristics of the patients
and GSVs are given in Table 1. Patients preferred day-case
treatment under regional or general anaesthesia in 49 (82%)
cryostripping procedures and in 38 (66%) EVLA procedures.
None of the patients had complications in hospital or
needed re-operation. Three wound complications occurred
in the cryostripping group, but the influence of thesecomplications was limited; one patient needed additional
wound care. At 6 weeks, residual tributaries were treated
by sclerotherapy with 1% polidocanol (Aethoxysclerol,
Kreussler, Germany) (cryostripping, nZ 33; EVLA, nZ 36)
and Mu¨ller phlebectomy (cryostripping, nZ 2; EVLA,
nZ 1).
After EVLA, the GSV segment was ablated completely in
57 patients (95%) at 6 months. In the cryostripping group,
the introduction of the flexible-tip probe to the below-knee
GSV was successful in all 60 patients, and the GSV was
stripped completely. At 24 months after treatment, re-
canalisation of the GSV or the GSV tract was not observed in
Table 3 Costs (V), QALY (SF-6D) gained and cost-effectiveness ratios (cost in V per QALY) for cryostripping and endovenous
laser and for the subsequent strategy analysis
Cryostripping Endovenous laser p-value
Mean 95% CIa Mean 95% CIa
All patients
Costs 2651 2501e2820 2783 2638e2937 0.234
QALY 1.59 1.53e1.64 1.60 1.55e1.64 0.824
Cost-effectiveness ratio 1730 1591e1891 1760 1633e1898 0.788
Day-case
Costs 2663 2503e2849 2804 2647e2980 0.272
QALY 1.58 1.51e1.65 1.61 1.54e1.68 0.628
Cost-effectiveness ratio 1758 1595e1972 1748 1603e1913 0.934
Outpatient
Costs 2595 2158e3104 2746 2491e3043 0.566
QALY 1.61 1.51e1.69 1.58 1.51e1651 0.594
Cost-effectiveness ratio 1623 1317e1920 1783 1561e2003 0.406
Outpatient and 50% reduced price of EVLA kit
Costs 2595 2158e3104 2586 2331e2883 0.982
QALY 1.61 1.51e1.69 1.58 1.51e1.65 0.594
Cost-effectiveness ratio 1623 1317e1920 1681 1462e1898 0.770
Values are mean. QALY, quality-adjusted life year.
a Bootstrapping 95% confidence interval (CI). An accurate estimate of the absolute and pertaining 95% CI was obtained using 500
bootstrapping replications of the trial.
Table 4 Incremental cots-effectiveness ratio at 2 years
Incremental cost-
effectiveness
(cost in V per QALY)
95% CIa
All patients 32 240 to 173
Day-cases 9 251 to 276
Outpatients 148 524 to 257
Outpatient,
50% reduced EVLA kit
46 421 to 358
QALY, quality of life year (SF-6D).
a Bootstrapping 95% confidence interval (CI). An accurate
estimate of the absolute and pertaining 95% CI was obtained
using 500 bootstrapping replications of the trial.
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overall freedom from duplex-defined varicose vein recur-
rence in 77% of patients after EVLA and in 66% after cry-
ostripping (pZ 0.25). Recurrent varicose veins detected on
duplex ultrasound and requiring additional treatment were
recorded in 19 (32%) patients who underwent cryostripping
(saphenopopliteal junction (SPJ) ligation, nZ 2; scle-
rotherapy, nZ 17), and in 13 (22%) patients who underwent
EVLA (saphenofemoral junction (SFJ) ligation, nZ 3; scle-
rotherapy, nZ 8 and SPJ ligation, nZ 2). No lost working
days were recorded for the patients with recurrent varicose
veins requiring additional treatment.
Over the total study period, mean SF-6D scores improved
slightly from 0.78 (standard deviation (SD) 0.11) at baseline
to 0.80 (SD 0.11) at 2 years for patients who underwent
cryostripping and from 0.77 (SD 0.11) to 0.79 (SD 0.12) for
patients who underwent EVLA, representing a 2.5% and
2.6% improvement from baseline, respectively. The quality-
adjusted SF-6D, calculated in terms of QALYs by deter-
mining the individual area under the curve, was 1.59 (95%
CI 1.53e1.64) gained for patients who underwent cry-
ostripping and 1.60 QALYs (95% CI 1.55e1.64) gained for
patients who underwent EVLA at 2-year follow-up.
Table 2 provides details of the costs of cryostripping and
EVLA during the 2-year follow-up. The costs of day-case
treatment were higher because of the higher costs of the
operating room and hospital stay. Additional equipment
costs were higher in the EVLA group because of significantly
higher charges of purchase and depreciation of the laser
apparatus and the duplex ultrasound machine. Disposables
were significantly more expensive in the EVLA group and, in
particular, the use of the EVLA kit was a cost-driver.
Patients in the cryostripping group returned to work after
2.2 (range: 0e14) days on average and in the EVLA groupafter 1.3 (range: 0e6) days on average (pZ 0.13). The cost
of lost productivity was V17 812 and V10 262 in the cry-
ostripping group and EVLA group, respectively. Self-
employed patients were significantly more likely than
employees to return to work directly. In the cryostripping
group, 11 of 12 (92%) self-employed people returned to
work directly and 8 of 27 (30%) of people in paid employ-
ment: in the EVLA group the data were 7 of 7 (100%) and 19
of 33 (77%), respectively. No lost working days were
recorded for the patients during follow-up.
The results of bootstrapping and the subsequent strat-
egies comparing day-case treatment, outpatient treatment
and outpatient treatment in combination with 50% reduced
price of EVLA kit are presented in Table 3. Comparing
cryostripping and EVLA, the cost-effectiveness ratio (cost in
V per QALY gained) was in favour of cryostripping: 1730
(95% CI 1591e1891) versus 1760 (95% CI 1633e1898),
respectively. With regard to different strategies, and in
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Figure 1 Cost-effectiveness planes of cryostripping and endovenous laser (EVLA) for A: all patients, B: day-case strategy, C:
outpatient strategy and D: outpatient and 50% reduced price of laser kit. The cost-effectiveness plane consists of four quadrants. A
dot to the left of the Y-axis means that cryostripping yields a better outcome, whereas a dot to the right means the endovenous
laser yields a better outcome. Likewise a dot above the X-axis means that the costs of EVLA are higher, whereas a dot below the X-
axis means that cryostripping is more expensive. The upper-left and the lower-right and upper-left quadrants indicate that both
costs and effects are favourable (dominant) for cryostripping and EVLA, respectively.
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gained), outpatient cryostripping appeared to be the better
strategy, that is, was less costly and more effective 2 years
after treatment. Comparing outpatients’ treatment and the
50% reduced price for the EVLA kit, the cost-effectivenessratio (cost in V per QALY gained) was still in favour of
outpatient cryostripping but only a limited difference
remained: 1623 (95% CI 1317e1920) for outpatient cry-
ostripping and V1681 (95% CI 1462e1898) for outpatient
EVLA and 50% reduced price for the EVLA kit. The results of
362 B.C.V.M. Disselhoff et al.bootstrapping and the incremental cost-effectiveness ratio
are presented in Table 4. The incremental cost-effective-
ness ratio was in favour of outpatient cryostripping; V148
(95 CI e524 to 527) per QALY at 2-year follow-up.
Results of the bootstrapping and the subsequent strat-
egies are depicted in cost-effectiveness planes in Fig. 1.
The QALY (SF-6D) gained panel (Fig. 1A) showed that most
replicas (53%) lie in the right-upper quadrant indicating
that EVLA yielded a better outcome in terms of QALY and
was more expensive. For day-case treatment (Fig. 1B),
most replicas lie in the right-upper quadrant indicating that
EVLA was more effective and more costly. In case of
outpatient treatment (Fig. 1C), most replicas lie in the left-
upper quadrant indicating that cryostripping was more
effective and less costly. For 50% reduced EVLA kit and
outpatient treatment (Fig. 1D), most replicas were in the
left-upper quadrant indicating that cryostripping was more
effective and less costly.
Discussion
This study compared the costs and cost-effectiveness of
cryostripping and EVLA with a follow-up of 2 years. The
results indicate that for patients with varicose veins and
GSV reflux, outpatient cryostripping appeared to be the
dominant strategy in terms of costs per QALY (SF-6D)
gained, but EVLA yielded comparable outcomes for a rela-
tively little additional cost. While the time to return to
work and costs of lost productivity were in favour of EVLA,
the total costs of EVLA were higher than those for
cryostripping.
To our knowledge, this study is the first to report on the
economic evaluation of an RCT comparing cryostripping and
EVLA with a 2-year follow-up. Most patients in both groups
(cryostripping, 58%; EVLA, 67%) were relatively young (<50
years), healthy adults with uncomplicated varicose veins
(C2EpAS3Pr CEAP classification). To eliminate technical
factors influencing the outcome of treatment, we per-
formed a single-centre study, with one consultant surgeon
equally experienced in both techniques and with no pref-
erence. The results of the clinical trial indicated that cry-
ostripping and EVLA were equally effective in patients with
varicose veins, but that patients favoured EVLA because of
better cosmetic results, lower rates of postoperative
morbidity and less impairment of normal activities up to 2
years. The results are comparable to recent published
findings.13 In addition, we found no significant differences
between the groups regarding clinical outcome measured
with SF-6D scores.
In the present cost comparison, the cost of the laser
apparatus, fibre kit and the duplex ultrasound were major
factors that raised the costs of EVLA group. In contrast,
hospital stay and anaesthesia (conduction or general) were
important factors that raised the cost of cryostripping.
Day-case procedures significantly increased the cost of
both interventions. Sick leave was shorter than that
reported in other studies,1,3,9 probably because we
included many self-employed patients who were signifi-
cantly more likely to return to work directly than paid
employees. The cost of lost productivity increased the cost
of cryostripping (V17 812 vs. V10 262) and accounted for
13.6% (vs. 7.4%) of the total cost of treatment. Theproportion and costs of additional procedures performed 6
weeks after treatment and during the follow-up period
were comparable: V27 784 for cryostripping and V28 783
for EVLA, and accounted for 17.3% and 17.5% of the total
cost of treatment, respectively. When comparing day-case
and outpatient procedures, we found the incremental
cost-effectiveness ratio to be in favour of the outpatient
cryostripping procedure. In the Netherlands, the costs for
day-case or outpatient treatment are independent of the
operative technique. This means that reducing additional
costs will overcome the cost disadvantage of EVLA. When
we compared outpatient cryostripping with outpatient
EVLA and 50% reduced EVLA kit, the cost-effectiveness
ratio was V1623 (95% CI 1317e1920) per QALY gained for
cryostripping and V1681 (95% CI 1547e1744) per QALY
gained for outpatient EVLA e only a limited difference of
V46 per QALY gained.
A possible limitation of this study is that readers will
have to accept that it applies to the Netherlands and
a direct comparison or application of our results to other
health-care systems may not be possible. We feel, however,
that the details provided herein on the various input data
and the sensitivity analyses performed will allow the
readers to judge whether a study in their setting would
have resulted in different overall results.
In conclusion, in this study, the outcome of cryostripping
and EVLA is similar. In terms of costs per QALY (SF-6D)
gained, outpatient cryostripping appeared to be the domi-
nant strategy, but EVLA yielded comparable outcomes for
a relatively little additional cost.
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